Cargando…
The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting
BACKGROUND/AIMS: The most common cancer among men and the third most common among women in Saudi Arabia is colon cancer. This study aimed to evaluate the yield of the fecal occult blood test (FOBT) used as a screening tool for colon cancer. SETTINGS AND DESIGN: Medical records of all patients above...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638621/ https://www.ncbi.nlm.nih.gov/pubmed/36352920 http://dx.doi.org/10.4103/jfmpc.jfmpc_16_22 |
_version_ | 1784825460372275200 |
---|---|
author | Almoneef, Naif M. Alkhenizan, Abdullah H. Mahmoud, Ahmed S. Alsoghayer, Suad A. Aldheshe, Abdulaziz A. |
author_facet | Almoneef, Naif M. Alkhenizan, Abdullah H. Mahmoud, Ahmed S. Alsoghayer, Suad A. Aldheshe, Abdulaziz A. |
author_sort | Almoneef, Naif M. |
collection | PubMed |
description | BACKGROUND/AIMS: The most common cancer among men and the third most common among women in Saudi Arabia is colon cancer. This study aimed to evaluate the yield of the fecal occult blood test (FOBT) used as a screening tool for colon cancer. SETTINGS AND DESIGN: Medical records of all patients above the age of 50 years who had visited the Family Medicine clinic at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia and who had undergone the FOBT screening between January 2002 and March 2017 were retrospectively reviewed. MATERIALS AND METHODS: We collected patients’ demographic data, FOBT results, and colonoscopy pathology reports results. STATISTICAL ANALYSIS: Data were analyzed using the Statistical Package for Social Science Version 25 (IBM Corp., Armonk, NY, USA). RESULTS: We included 2179 patients in this study. The mean age was 59.8 ± 8 years. As a result of the FOBT screening, 19.7% of the patients had a positive FOBT. Colon cancer accounted for 3.5% of all abnormal colonoscopy pathology reports. The Saudi age-standardized incidence rate (ASIR) in our study was 26.56 per 100,000 persons. CONCLUSION: FOBT is a feasible tool that can be used for colon cancer screening in primary care settings. The Saudi ASIR in our study was higher than the Saudi Cancer Registry, but it was still lower in comparison to other countries. We recommend the establishment of a national community-based colon cancer screening program. |
format | Online Article Text |
id | pubmed-9638621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-96386212022-11-08 The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting Almoneef, Naif M. Alkhenizan, Abdullah H. Mahmoud, Ahmed S. Alsoghayer, Suad A. Aldheshe, Abdulaziz A. J Family Med Prim Care Original Article BACKGROUND/AIMS: The most common cancer among men and the third most common among women in Saudi Arabia is colon cancer. This study aimed to evaluate the yield of the fecal occult blood test (FOBT) used as a screening tool for colon cancer. SETTINGS AND DESIGN: Medical records of all patients above the age of 50 years who had visited the Family Medicine clinic at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia and who had undergone the FOBT screening between January 2002 and March 2017 were retrospectively reviewed. MATERIALS AND METHODS: We collected patients’ demographic data, FOBT results, and colonoscopy pathology reports results. STATISTICAL ANALYSIS: Data were analyzed using the Statistical Package for Social Science Version 25 (IBM Corp., Armonk, NY, USA). RESULTS: We included 2179 patients in this study. The mean age was 59.8 ± 8 years. As a result of the FOBT screening, 19.7% of the patients had a positive FOBT. Colon cancer accounted for 3.5% of all abnormal colonoscopy pathology reports. The Saudi age-standardized incidence rate (ASIR) in our study was 26.56 per 100,000 persons. CONCLUSION: FOBT is a feasible tool that can be used for colon cancer screening in primary care settings. The Saudi ASIR in our study was higher than the Saudi Cancer Registry, but it was still lower in comparison to other countries. We recommend the establishment of a national community-based colon cancer screening program. Wolters Kluwer - Medknow 2022-08 2022-08-30 /pmc/articles/PMC9638621/ /pubmed/36352920 http://dx.doi.org/10.4103/jfmpc.jfmpc_16_22 Text en Copyright: © 2022 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Almoneef, Naif M. Alkhenizan, Abdullah H. Mahmoud, Ahmed S. Alsoghayer, Suad A. Aldheshe, Abdulaziz A. The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting |
title | The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting |
title_full | The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting |
title_fullStr | The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting |
title_full_unstemmed | The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting |
title_short | The yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting |
title_sort | yield of fecal occult blood testing as a screening tool for colon cancer in a primary care setting |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638621/ https://www.ncbi.nlm.nih.gov/pubmed/36352920 http://dx.doi.org/10.4103/jfmpc.jfmpc_16_22 |
work_keys_str_mv | AT almoneefnaifm theyieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting AT alkhenizanabdullahh theyieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting AT mahmoudahmeds theyieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting AT alsoghayersuada theyieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting AT aldhesheabdulaziza theyieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting AT almoneefnaifm yieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting AT alkhenizanabdullahh yieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting AT mahmoudahmeds yieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting AT alsoghayersuada yieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting AT aldhesheabdulaziza yieldoffecaloccultbloodtestingasascreeningtoolforcoloncancerinaprimarycaresetting |